Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED +0.49%78 ROC (Joel Greenblatt) % is 7.67% as of Mar. 2026, which is 71% above its 10-year median of 4.49. GuruFocus rates XTER:MED with a GF Score™ of 78/100 and a GF Value™ of €3.04 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 665 Healthcare Providers & Services companies, MediClin AG ranks worse than 51.73% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. MediClin AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.67%.
The historical rank and industry rank for MediClin AG's ROC (Joel Greenblatt) % or its related term are showing as below:
XTER:MED'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.04 Med: 4.49 Max: 12.77
Current: 11.81
During the past 13 years, MediClin AG's highest ROC (Joel Greenblatt) % was 12.77%. The lowest was 0.04%. And the median was 4.49%.
XTER:MED's ROC (Joel Greenblatt) % is ranked worse than 51.73% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 12.49
vs XTER:MED: 11.81
MediClin AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 153.70% per year.
MediClin AG (XTER:MED) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
MediClin AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for MediClin AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:MED vs HCA, THC, DVA: ROC (Joel Greenblatt) % Comparison
For the Medical Care Facilities subindustry, MediClin AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where MediClin AG's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 7.67% mean?
MediClin AG (XTER:MED) has a ROC (Joel Greenblatt) % of 7.67% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on MediClin AG and its competitors. This is 71% above median its historical median of 4.49. Over the past decade, MediClin AG's ROC (Joel Greenblatt) % has ranged from 0.04 to 12.77. According to the industry distribution chart, MediClin AG ranks #344 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 51.7%.
Is MediClin AG's ROC (Joel Greenblatt) % too high?
MediClin AG's current ROC (Joel Greenblatt) % of 7.67% is 71% above median its 10-year median of 4.49. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 12.77. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.49. MediClin AG's value of 7.67% is 38.6% below this industry median. Based on the distribution chart, MediClin AG ranks #344 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MediClin AG has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's ROC (Joel Greenblatt) % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #344 out of 665 companies for ROC (Joel Greenblatt) %. This places MediClin AG in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.49. MediClin AG's value of 7.67% is 38.6% below this benchmark. Historically, MediClin AG's own ROC (Joel Greenblatt) % has ranged from 0.04 to 12.77 over the past decade. While the company's 10-year median is 4.49 vs. the industry median of 12.49, MediClin AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.49, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediClin AG's current ROC (Joel Greenblatt) % of 7.67% is 38.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current ROC (Joel Greenblatt) % is 7.67%, which is 71% above median its own 10-year median of 4.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.04, compared to a current price of €4.12 — trading 35.5% above its estimated fair value. The current ROC (Joel Greenblatt) % is 7.67%, which is 71% above median its 10-year median of 4.49 and 38.6% below the Healthcare Providers & Services industry median of 12.49. MediClin AG's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current ROC (Joel Greenblatt) % is 7.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €4.12 is trading 35.5% above its estimated GF Value™ of €3.04.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
ROC (Joel Greenblatt) %: 7.67% (71% above median its 10-year median of 4.49)
GF Value™: €3.04 vs. price of €4.12 (35.5% above fair value)
Industry Position: 38.6% below the Healthcare Providers & Services median (#344 of 665)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
78GF Score
Get the complete analysis for XTER:MED
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
